期刊文献+

卵巢储备正常者COH不同阶段添加高纯度人绝经期促性腺激素对IVF-ET结局的影响 被引量:6

Effects of highly purified human menopausal gonadotrophin(HP-hMG) supplementation on IVF-ET outcomes in patients with normal ovarian reserve during different periods of controlled ovarian hyperstimulation
原文传递
导出
摘要 目的:探讨卵巢储备正常者在促排卵不同阶段添加高纯度人绝经期促性腺激素(highly purified human menopausal gonadotrophin,HP-hMO)对体外受精.胚胎移植(WF-ET)结局的影响。方法:收集接受IVF或单精子胞质内显微注射技术(ICSll治疗的25~35岁卵巢储备功能正常的患者(n=153),根据是否添加HP-hMG及添加时机分为A组(未添加HP—hMG),B组(Gn第1日添加HP—hMG)和C组(Gn第6~8日添加HP.hMG),分析三组妊娠结局。结果:A组hCG注射日LH、E2水平低于B组及C组(P〈0.05),A组hCG注射目P水平高于B组及C组(P〈0.05),获卵数及MII卵子数A组及C组高于B组(P〈0.05),优质胚胎率B组高于A组及C组(P〈0.05),累积妊娠率,C组(85%)高于A组(59.3%)及B组(67.6%),差异有统计学意义(P〈0.05),3组受精率、成熟卵率、种植率差异无统计学意义(P〈0.05)。结论:卵巢储备功能正常者在采用标准长方案促排卵时,中晚期添加HP.hMG可改善累积妊娠结局;卵泡发育不同阶段添加HP—hMG,可能适用于不同的人群。 Objective: To explore the effects of highly purified human menopausal gonadotrophin (HP- hMG) supplementation on in vitro fertilization-embryo transfer (IVF-ET) outcomes in patients with normal ovarian reserve during different periods of controlled ovarian hyperstimulation (COH). Methods: The patients (n=153) with normal ovarian reserve who accepted IVF or a maceral intracytoplasmic sperm inject/on (ICSI) technology treatment were collected. According to whether supplement HP-hMG and supplementation time, the patients were divided into three groups, group A: did not supplement HP-hMG, group B: supplement HP-hMG on day 1 of Gonadotropin (Gn) therapy, group C: supplement HP-hMG on day 6-8 of Gn therapy. The clinical outcomes were compared among the three groups. Results: There were significant differences in serum LH, E2 and P levels on the day ofhCG administration among groups A, B and C (P〈0.05). The number of oocytes retrieved and mature oocytes was significantly higher in groups A and C compared with group B (P〈0.05). The high-quality embryo rate was significantly higher in group B compared with groups A and C (P〈0.05), the cumulative clinical pregnancy rate in group C was higher than that in groups A and B, which showed a significant difference between groups C and A (P〈0.05), there were no significant differences in the rates of fertilization, mature oocyte and implantation among the three groups (P〉0.05). Conclusion: Patients with normal ovarian reserve, when using standard long methods for stimulating ovulation, supplementation of HP-hMG in the middle and late follicle phases can improve pregnancy outcome. Different periods of COH of supplementing HP-hMG may apply to different patients.
出处 《生殖与避孕》 CAS CSCD 北大核心 2016年第9期769-773,共5页 Reproduction and Contraception
基金 四川省教育厅重点项目 项目号:15ZA0097
关键词 高纯度人绝经期促性腺激素(HP—hMG) 体外受精(IVF) 妊娠结局 highly purified human menopausal gonadotrophin (HP-hMG) in vitro fertilization (IVF) pregnancy outcome
  • 相关文献

参考文献18

  • 1Gordon UD, Harrison RF, Fawzy M, et al. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril, 2001, 75(2):324-3 1.
  • 2Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod, 2000, 15(5):1003-8.
  • 3Smitz J, Andersen AN, Devroey P, et al. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod, 2007, 22(3):676-87.
  • 4Hugues JN. Impact of 'LH activity' supplementation on serum progesterone levels during controlled ovarian stimulation: a systematic review. Hum Reprod, 2012, 27 (1):232-43.
  • 5Nikas G, Develioglu OH, Toner JP, et al. Endometrial pinopodes indicate a shift in the window of receptivity in IVF cycles. Hum Reprod, 1999, 14(3):787-92.
  • 6谭欣,贺贞,左涛,郭建,杨丹,朱明辉.血清和卵泡液中雌激素及孕激素水平及其比值与获卵数和妊娠结局的关系[J].实用妇产科杂志,2014,30(3):216-219. 被引量:9
  • 7Kovacs P, Kovats T, Kaali SG. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertil Steril, 2010, 93(2):475-9.
  • 8Weghofer A, Munn6 S, BrannathW, et al. The impact of LH containing gonadotropins on diploidy rates in preimplanta- tion embryos: long protocol stimulation. Hum Reprod, 2008, 23(3):499-503.
  • 9Kim Y J, Ku SY, Jee BC, et al. Tri-pronucleated zygotes may occur less frequently in luteinizing hormone activity-added cycles. Gynecol Endocrinol, 2011, 27(7):458-63.
  • 10Platteau P, Nyboe Andersen A, Loft A, et al. Highly purified hMG versus recombinant FSH for ovarian stimulation in IVF cycles. Reprod Biomed Online, 2008, 17(17): 190-8.

二级参考文献35

  • 1Ruvolo G, Bosco L, Pane A, et al. Lower apoptosis rate inhuman cumulus cells after administration of recombinantluteinizing hormone to women undergoing ovarian stimula-tion for in vitro fertilization procedures. Fertil Steril, 2007,87(3):542-4.
  • 2Kolibianakis EM,Collins J,Tarlatzis B, et al. Are endogenousLH levels during ovarian stimulation for IVF using GnRHanalogues associated with the probability of ongoingpregnancy? A systematic review. Hum Reprod Update, 2006,12(1):3-12.
  • 3Higgins J, Green S. Cochrance Handbook for SystematicReviews of Interventions Version 5.1.0[updated March 2011] .The Cochrane Collaboration, 2011. Available from www.cochranehand-book.org.
  • 4Fabregues F, Iraola A,Casals G, et al. Evaluation of two dosesof recombinant human luteinizing hormone supplementa-tion in down-regulated women of advanced reproductive ageundergoing follicular stimulation for IVF: a randomized clini-cal study. Eur J Obstet Gynecol Reprod Biol, 2011,158(5):56-61.
  • 5Fabregues F, Creus M,Penarrubia J,et al. Effects of recom-binant human luteinizing hormone supplementation on ova-rian stimulation and the implantation rate in down-regulatedwomen of advanced reproductive age. Fertil Steril, 2006, 85(4):925-31.
  • 6Humaidan P, Bungum M,Bungum L, et al. Effects ofrecombinant LH supplementation in women undergoing as-sisted reproduction with GnRH agonist down-regulation andstimulation with recombinant FSH: an opening study. ReprodBiomed Online, 2004, 8(6):635-43.
  • 7Marrs R, Meldrum D,Muasher S, et al. Randomized trial tocompare the effect of recombinant human FSH (follitropinalfa) with or without recombinant human LH in women un-dergoing assisted reproduction treatment. Reprod BiomedOnline, 2004, 8(2):175-82.
  • 8Matorras R, Prieto B, Exposito A, et al. Mid-follicular LHsupplementation in women 35-39 years undergoing ICSIcycles: a randomized controlled study. Reprod BiomedOnline, 2009, 19(6):879-87.
  • 9NyboeAndersen A, Humaidan P, Fried G, et al. RecombinantLH supplementation to recombinant FSH during the finaldays of controlled ovarian stimulation for in vitro fertilization.A multicentre, prospective, randomized, controlled trial. HumReprod, 2008, 23(2):427-34.
  • 10Tarlatzis B,Tavmergen E,Szamatowicz M, et al. The use ofrecombinant human LH (lutropin alfa) in the late stimulationphase of assisted reproduction cycles: a double-blind,randomized, prospective study. Hum Reprod, 2006, 21(1):90-4.

共引文献8

同被引文献39

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部